Triple negative breast cancer (TNBC) has increased recurrence and poor survival, despite a high response rate to neoadjuvant chemotherapy. The aim of this study was to determine whether current drug treatment(s) eliminates bulk of tumor cells, but it has a minimal effect on cancer stem cells (CSCs) leading to tumor recurrence. We studied the effects of PARP inhibitors (AZD2281 and BSI-201), paclitaxel, docetaxel, cisplatin and cisplatin plus TRAIL on CSCs derived from CRL-2335 and MDA-MB-468 TNBC cells in vitro. The in vitro data indicate that cisplatin plus TRIAL treatment was most effective in eliminating CSCs compared to PARP inhibitors, cisplatin, paclitaxel and docetaxel. Treatment with cisplatin plus TRAIL also inhibits Wnt-1 signaling and its downstream target, β-catenin, phospho β-catenin, cyclin D1, increased apoptosis, reduced proliferation and mammosphere formation. Inhibition of Wnt-1 by siRNA significantly reduced the ability of CSCs to form mammospheres compared to control. However, maximum effect was seen in cisplatin plus TRAIL-treated cells. Taken together the data suggest that cisplatin plus TRAIL treatment has the potential of providing a new strategy for improving the therapeutic outcome in TNBC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889134 | PMC |
| http://dx.doi.org/10.3892/ijo.2011.1085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cisplatin-encapsulated TRAIL-engineered exosomes from human chorion-derived MSCs for targeted cervical cancer therapy.
Stem Cell Res Ther
November 2024
Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, No. 109 Xueyuan Xi Road, Wenzhou, Zhejiang, 325027, China.
Article Synopsis
- Cisplatin (DDP) is a common chemotherapy drug used for treating cervical cancer, particularly in advanced cases or for patients wishing to preserve fertility; TRAIL is a protein that can selectively induce death in cancer cells.
- Human chorion-derived mesenchymal stem cells (hCD-MSCs) were modified to enhance TRAIL production and their exosomes (hCD-MSCs-Exo) were developed as delivery vehicles for DDP via a method called electroporation.
- The combination of DDP and hCD-MSCs-Exo demonstrated improved effectiveness in reducing cancer cell proliferation and promoting apoptosis in vitro and in vivo, with minimal toxicity, indicating a promising therapeutic approach for cervical cancer treatment.
Pomalidomide sensitizes lung cancer cells to TRAIL/CDDP-induced apoptosis via directly targeting electron transfer flavoprotein alpha subunit.
Bioorg Chem
December 2024
State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Science and Technology of China, Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, China. Electronic address:
Article Synopsis
- Pomalidomide, a stronger drug than thalidomide, could help treat lung cancer when combined with other drugs.
- Researchers found that it targets an important enzyme called ETFA, which helps produce energy in cancer cells.
- The study suggests that by boosting energy production, pomalidomide helps make cancer cells more likely to die, especially when used with a drug called cisplatin.
TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction.
Pathol Res Pract
November 2024
Cellular Biology, Research and Development Department, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil; Translational Research Laboratory in Oncology, Mário Penna Institute, Belo Horizonte, MG, Brazil. Electronic address:
Article Synopsis
- Ovarian cancer (OC) is difficult to diagnose and has high relapse rates (up to 90% with standard chemotherapy), highlighting the need for new molecular markers to assess treatment response and disease progression.
- This study investigated the resistance of three ovarian tumor cell lines (SKOV-3, TOV-21G, OV-90) to cisplatin and paclitaxel, finding that SKOV-3 was the most resistant to both drugs.
- Notably, after cisplatin treatment, TNFRSF10D expression increased significantly in the resistant SKOV-3 cells, suggesting that this receptor could be a potential biomarker for chemoresistance in ovarian cancer.
Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure.
Oncotarget
May 2024
Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 infection has led to worsened outcomes for patients with cancer. SARS-CoV-2 spike protein mediates host cell infection and cell-cell fusion that causes stabilization of tumor suppressor p53 protein. In-silico analysis previously suggested that SARS-CoV-2 spike interacts with p53 directly but this putative interaction has not been demonstrated in cells.
View Article and Find Full Text PDFInhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells.
Biol Chem
June 2024
Department of Cytokinetics, 86853 Institute of Biophysics of the Czech Academy of Sciences, Královopolská 135, CZ-612 65 Brno, Czech Republic.
Checkpoint kinase 1 (Chk1) plays an important role in regulation of the cell cycle, DNA damage response and cell death, and represents an attractive target in anticancer therapy. Small-molecule inhibitors of Chk1 have been intensively investigated either as single agents or in combination with various chemotherapeutic drugs and they can enhance the chemosensitivity of numerous tumor types. Here we newly demonstrate that pharmacological inhibition of Chk1 using potent and selective inhibitor SCH900776, currently profiled in phase II clinical trials, significantly enhances cytotoxic effects of the combination of platinum-based drugs (cisplatin or LA-12) and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) in human prostate cancer cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!